Global Investor Forum Contact

René Bernards

Founder, Qameleon Therapeutics & Professor of molecular carcinogenesis, Netherlands Cancer Institute

Session

14:15 - 15:25
From research to innovation

René Bernards’ laboratory at the Netherlands Cancer Institute uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. He founded Qameleon Therapeutics to repurpose abandoned and patent expired drugs for use in cancer. Qameleon aims to bring these drugs to patients at sustainable prices by working with investors who seek societal impact and generic drug makers.

Abstract

How much longer will we put up with $100,000 cancer drugs?
The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. Qameleon Therapeutics was founded to enable the development of truly transformative drugs at sustainable prices. To do this, abandoned drugs that lacked sufficient single agent activity and patent expired drugs will be repurposed for new indications through innovative genetic approaches. These drugs will be re-introduced into the clinic with financial support from investors seeking societal impact next to a reasonable return on investment. A first example of a new clinical use of an old drug will be presented.

Kees Been
Lysosomal Therapeutics Inc.

Erik van de Berg
AM-Pharma

René Bernards
Qameleon Therapeutics & NKI

Annelien Bredenoord
UMC Utrecht

Carine van den Brink
AXON Lawyers

Danielle Curfs
Chemelot InSciTe
Jenny Dankelman
TU Delft
Diederik Dippel
Erasmus MC

Cornelia van Duijn
Erasmus MC

Lude Franke
UMCG
Thibault Helleputte
DNAlytics
Mark van Houdenhoven
St. Maartenskliniek
Henk Joos
Flanders Bio
Peter de Keizer
Erasmus MC
Tim Knotnerus
AM-Pharma, PRIMER Professionals
Angus Livingstone
Oncode Institute
Travis McCready
Massachusetts Life Sciences Center

Mirjam Mol
Pivot Park

Barend Mons
DTL & LUMC
Timothy Noël
Eindhoven University of Technology
Jacquelien Noordhoek
Dutch CF Foundation
Violet Petit-Steeghs
Athena Institute
Thomas Plochg
NPHF
Dirk Jan van der Pol
Ordina
Anne Portwich
LSP
Elisabeth van Rossum
Erasmus MC
André van de Sande
Xendo
Marlies Schijven
AMC
Hans Schikan
Topsector LSH
Hanneke Schuitemaker
Janssen Vaccines
Frits Schut
V.O. Patents & Trademarks
Marieke Schuurmans
UMC Utrecht
Jacob Seidell
VU
Agaath Sluijter
Medical Delta
Thijs Spigt
Erasmus MC
Marianne van der Steen
Maastricht University
Maarten Steinbuch
Eindhoven University of Technology
Onno van de Stolpe
Galapagos
Werner Verbiest
Janssen Diagnostics
Martine de Vries
LUMC

Edward van Wezel
BioGeneration Ventures

Jan van de Winkel
Genmab

Loek Winter
DC Klinieken

Hanneke Heeres
Health~Holland
Caroline Duterloo
Medical Delta
Paul Korte
Janssen
Aart Jan van der Lelij
Erasmus MC
Werner Brouwer
Erasmus University
Arnout van Diermen
Novo Nordisk

Ton van der Steen
Erasmus MC & Medical Delta

Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2018 Innovation for Health